Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Levitasbio Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. Each of these pending office actions is assigned to a different individual, resulting in a total of 3 distinct examiners involved in the company's current prosecution. This distribution indicates that the company's pending matters are being reviewed independently by multiple officials at the patent office.
The portfolio is also spread across multiple art units, which means the technical subject matter of the applications is reviewed by several specialized examination groups. MARTIN, PAUL C is identified as the busiest examiner for the company, currently overseeing the busiest examiner pending office action. Because the pending office actions are divided among the distinct examiners, no single examiner holds a majority of the workload. The alignment of the pending office actions with the distinct examiners and art units within the Biotechnology & Pharmaceuticals sector highlights a distributed prosecution landscape. This variety in examiners and art units requires the company to address the specific technical focus of each individual examination group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| EVANS, CHRISTOPHER RYAN | 1 | 60.9% | +64.3% |
| GORDON, BRIAN R | 1 | 65.2% | +18.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18045473 | METHODS AND SYSTEMS FOR LEVITATION-BASED MAGNETIC SEPARATION | EVANS, CHRISTOPHER RYAN | — |
| 18045472 | METHODS AND SYSTEMS FOR CELL SEPARATION | GORDON, BRIAN R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | MARTIN, PAUL C | — |
| 18045473 | METHODS AND SYSTEMS FOR LEVITATION-BASED MAGNETIC SEPARATION | EVANS, CHRISTOPHER RYAN | — |
| 18045472 | METHODS AND SYSTEMS FOR CELL SEPARATION | GORDON, BRIAN R | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1677 | 1 |
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19203107 | PARTICLE SEPARATOR SYSTEM, MATERIALS, AND METHODS OF USE | MARTIN, PAUL C | 1653 | §103§112DP | Non-Final OA | — | Pending | May 08, 2025 |
| 18045473 | METHODS AND SYSTEMS FOR LEVITATION-BASED MAGNETIC SEPARATION | EVANS, CHRISTOPHER RYAN | 1677 | §102§103 | Final Rejection | — | Pending | Oct 11, 2022 |
| 18045472 | METHODS AND SYSTEMS FOR CELL SEPARATION | GORDON, BRIAN R | 1798 | §102§103§112 | Final Rejection | — | Pending | Oct 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial